氯化卡咪唑铵抑制钙调蛋白与心肌CaV1.2通道结合的作用
郝明杰, 孙伟楠, 苏敬阳, 郝丽英中国医科大学药学院药物毒理学教研室, 沈阳 110122
收稿日期:
2021-12-08发布日期:
2022-11-09通讯作者:
苏敬阳E-mail:jysu@cmu.edu.cn作者简介:
郝明杰(1998-),女,硕士研究生.基金资助:
中国博士后科学基金(2021M693914);辽宁省中央引领地方科技发展专项(2020JH6/10500022);医学电生理学重点实验室(西南医科大学)开放基金(KeyME-2019-07);大学生创新训练项目(202110159007)关键词: 钙调蛋白拮抗剂, CaV1.2通道, Ca2+浓度, 心血管系统疾病
Abstract: Objective To investigate the inhibitory effect of calmidazolium chloride(CMZ),an antagonist of calmodulin(CaM),on the binding of CaM with CT1 protein motif at the C-terminus of the cardiac CaV1.2 channel using different concentrations of calcium ion(Ca2+). The intent was to provide a theoretical basis for the regulatory mechanism of intracellular Ca2+ concentration by CMZ and clinical application.Methods A glutathione S-transferase pull-down assay detected binding of CaM to the CT1 protein motif 100 nmol/L or 10 μmol/L Ca2+ with or without CMZ.Results CMZ inhibited CaM binding to the cardiac CaV1.2 channel CT1 protein motif at both Ca2+ concentrations. CaM binding to CT1 in the presence of CMZ was reduced compared with CaM without CMZ. Binding was dependent on the concentrations of CaM protein and Ca2+. Conclusion CMZ inhibits the binding of CaM to CT1 of the cardiac CaV1.2 channel,thereby regulating the activity of L-type Ca2+ channels.
Key words: calmodulin antagonist, CaV1.2 channnel, Ca2+ concentration, cardiovascular diseases
PDF全文下载地址:
https://journal.cmu.edu.cn/CN/article/downloadArticleFile.do?attachType=PDF&id=3103